{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:10:47Z","timestamp":1787501447345,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.braindev.2021.12.002","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T17:40:57Z","timestamp":1641231657000},"page":"308-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term efficacy of low-dose perampanel for progressive myoclonus epilepsy in a patient with Gaucher disease type 3"],"prefix":"10.1016","volume":"44","author":[{"given":"Mayu","family":"Tahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimichi","family":"Higurashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2021.12.002_b0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.yebeh.2016.06.041","article-title":"Efficacy and tolerability of perampanel in ten patients with Lafora disease","volume":"62","author":"Goldsmith","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.braindev.2021.12.002_b0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/epi.13662","article-title":"Perampanel in 12 patients with Unverricht-Lundborg disease","volume":"58","author":"Crespel","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.braindev.2021.12.002_b0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ebcr.2017.05.004","article-title":"Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA)","volume":"8","author":"Shiraishi","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.braindev.2021.12.002_b0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ebcr.2018.02.005","article-title":"Seizure remission and improvement of neurological function in sialidosis with perampanel therapy","volume":"10","author":"Hu","year":"2018","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.braindev.2021.12.002_b0025","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.clinph.2019.07.006","article-title":"Low-dose perampanel improves refractory cortical myoclonus by the dispersed and suppressed paroxysmal depolarization shifts in the sensorimotor cortex","volume":"130","author":"Oi","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.braindev.2021.12.002_b0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/jnnp.38.9.849","article-title":"Progressive myoclonic epilepsy due to Gaucher\u2019s disease in an adult","volume":"38","author":"King","year":"1975","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.braindev.2021.12.002_b0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1023\/A:1005319632539","article-title":"Neurological outcome of a patient with Gaucher disease type III treated by enzymatic replacement therapy","volume":"21","author":"Dobbelaere","year":"1998","journal-title":"J Inher Metab Dis"},{"key":"10.1016\/j.braindev.2021.12.002_b0040","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.0013-9580.2004.15904.x","article-title":"Early visual seizures and progressive myoclonus epilepsy in neuronopathic Gaucher disease due to a rare compound heterozygosity (N188S\/S107L)","volume":"45","author":"Filocamo","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.braindev.2021.12.002_b0045","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222304","article-title":"Progressive myoclonic epilepsy and horizontal gaze palsy: a rare aetiology","volume":"2017","author":"Singh","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.braindev.2021.12.002_b0050","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.braindev.2021.12.002_b0055","first-page":"361","article-title":"The unified myoclonus rating scale","volume":"89","author":"Frucht","year":"2002","journal-title":"Adv Neurol"},{"key":"10.1016\/j.braindev.2021.12.002_b0060","unstructured":"Russell DJ, Rosenbaum PL, Wright M, Avery LM, editors. Gross Motor Function Measure (GMFM-66 & GMFM-88) User\u2019s Manual. 2nd Edition. London: Mac Keith Press; 2013."},{"key":"10.1016\/j.braindev.2021.12.002_b0065","first-page":"6","article-title":"The functional independence measure: a new tool for rehabilitation","volume":"1","author":"Keith","year":"1987","journal-title":"Adv Clin Rehab"},{"key":"10.1016\/j.braindev.2021.12.002_b0070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng1238","article-title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy","volume":"35","author":"Chan","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.braindev.2021.12.002_b0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fnmol.2017.00347","article-title":"Regulation of AMPA receptor trafficking by protein ubiquitination","volume":"10","author":"Widagdo","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.braindev.2021.12.002_b0080","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1601-183X.2007.00305.x","article-title":"NEDD4-2 as a potential candidate susceptibility gene for epileptic photosensitivity","volume":"6","author":"Dibbens","year":"2007","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.braindev.2021.12.002_b0085","doi-asserted-by":"crossref","first-page":"e1006634","DOI":"10.1371\/journal.pgen.1006634","article-title":"Epilepsy-associated gene Nedd4-2 mediates neuronal activity and seizure susceptibility through AMPA receptors","volume":"13","author":"Zhu","year":"2017","journal-title":"PLOS Genet"},{"key":"10.1016\/j.braindev.2021.12.002_b0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neulet.2015.09.012","article-title":"Abnormally increased surface expression of AMPA receptors in the cerebellum, cortex and striatum of Cln3\u2212\/\u2212 mice","volume":"607","author":"Kov\u00e1cs","year":"2015","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.braindev.2021.12.002_b0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10571-016-0341-8","article-title":"The AMPAR antagonist perampanel attenuates traumatic brain injury through anti-oxidative and anti-inflammatory activity","volume":"37","author":"Chen","year":"2017","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.braindev.2021.12.002_b0100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.braindev.2020.08.008","article-title":"Perampanel may be beneficial in Leigh syndrome by its anti-oxidative but not anti-epileptic effect","volume":"43","author":"Finsterer","year":"2021","journal-title":"Brain Dev"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760421002308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760421002308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:50:10Z","timestamp":1759953010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760421002308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0387760421002308"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2021.12.002","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy of low-dose perampanel for progressive myoclonus epilepsy in a patient with Gaucher disease type 3","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2021.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}